Without U.S. rules, biotech food lacks investors

Without U.S. Rules, Biotech Food Lacks Investors
By ANDREW POLLACK New York Times, July 30 2007http://www.nytimes.com/2007/07/30/washington/30animal.html?ref=health

But industry executives and some former agency officials said it was unlikely that Congress would enact totally new laws for transgenic animals. And using the drug laws, they say, would provide tighter control than an alternative approach of using the rules governing food additives. Agency officials have said that the veterinary drug rules would be used, and they have already been overseeing some experimental work on that basis. But they continued to debate the issue, and the policy has never been made official.

g rules would be interpreted for transgenic animals, and what types of data would be needed to prove safety and efficacy. But there are open questions about how the drug rules would actually translate. While a chemical drug must be shown to be consistent and stable, for instance, it is unclear how that standard would apply to a gene passed from generation to generation. Some critics say that while the drug rules do provide fairly strict regulation of food safety, there are drawbacks to adapting that approach. Because applications for approval of drugs are confidential, for instance, there would be no opportunity for public comment before the agency acted.

Another worry is that the F.D.A. might not have enough expertise or authority to conduct a vigorous review of the environmental impact of transgenic animals. The F.D.A. has dismissed this concern, however, saying it has sufficient expertise and can consult with other agencies.

INTRODUCTION TO GM

GENE EDITING MYTHS, RISKS, & RESOURCES

Without U.S. rules, biotech food lacks investors

Menu

Resources

Contacts